Similar articles for PMID: 37097678

Year	Number of Results
2010	1
2012	1
2013	1
2014	1
2015	3
2016	14
2017	12
2018	12
2019	9
2020	25
2021	14
2022	15
2023	3
2024	0

1

Somatic Variants in DNA Damage Response Genes in Ovarian Cancer Patients Using Whole-exome Sequencing.

Lopacinska-Joergensen J, Oliveira DVNP, Poulsen TS, Hoegdall CK, Hoegdall EV. Lopacinska-Joergensen J, et al. Anticancer Res. 2023 May;43(5):1891-1900. doi: 10.21873/anticanres.16348. Anticancer Res. 2023. PMID: 37097678

2

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.

Cerrato A, Morra F, Celetti A. Cerrato A, et al. J Exp Clin Cancer Res. 2016 Nov 24;35(1):179. doi: 10.1186/s13046-016-0456-2. J Exp Clin Cancer Res. 2016. PMID: 27884198 Free PMC article. Review.

3

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.

Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ. Eoh KJ, et al. BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y. BMC Cancer. 2020. PMID: 32164585 Free PMC article.

4

[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].

Škapa P, Dundr P. Škapa P, et al. Cesk Patol. 2016 Fall;52(4):199-204. Cesk Patol. 2016. PMID: 27869446 Review. Czech.

5

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.

Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N. Waks AG, et al. Ann Oncol. 2020 May;31(5):590-598. doi: 10.1016/j.annonc.2020.02.008. Epub 2020 Feb 20. Ann Oncol. 2020. PMID: 32245699 Free PMC article.

6

Clinical assays for assessment of homologous recombination DNA repair deficiency.

Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF. Stover EH, et al. Gynecol Oncol. 2020 Dec;159(3):887-898. doi: 10.1016/j.ygyno.2020.09.029. Epub 2020 Oct 2. Gynecol Oncol. 2020. PMID: 33012552 Review.

7

Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.

Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, Joseph P, Sobeck AM, O'Connor CM, Raines B, Gandhi A, Dziubinski ML, Ma DS, Resnick K, Singh S, Zanotti K, Nagel C, Waggoner S, Thomas DG, Skala SL, Zhang J, Narla G, DiFeo A. Avelar RA, et al. Mol Cancer Ther. 2023 May 4;22(5):599-615. doi: 10.1158/1535-7163.MCT-21-0880. Mol Cancer Ther. 2023. PMID: 36788429 Free PMC article.

8

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.

Voutsadakis IA, Stravodimou A. Voutsadakis IA, et al. Anticancer Res. 2023 Mar;43(3):967-981. doi: 10.21873/anticanres.16241. Anticancer Res. 2023. PMID: 36854505 Review.

9

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.

Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG. Sahnane N, et al. Int J Mol Sci. 2020 Dec 19;21(24):9708. doi: 10.3390/ijms21249708. Int J Mol Sci. 2020. PMID: 33352687 Free PMC article.

10

[BRCA1 and BRCA2 - pathologists starting kit].

Škapa P. Škapa P. Cesk Patol. 2016 Fall;52(4):193-196. Cesk Patol. 2016. PMID: 27869444 Czech.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year